Skip to main content
CBIO logo

CBIO · Crescent Biopharma, Inc. · Executive Compensation

Track CBIO — free
$13.00 +0.09 (+0.70%) At close · Nov 20
Market Cap
$505.64M
Shares
38.90M
Volume · Nov 20 422.38K Avg daily vol (3M) 358.97K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

No Compensation Data

No Summary Compensation Table has been imported from this company's proxy statements yet.

Executive changes

Person Change Filed
Amy Reilly Appointed 2025-07-31
Rick Scalzo Appointed 2025-07-31
David Lubner Appointed 2025-07-31
Tanya Sengupta Appointed 2025-07-31
Jan Pinkas Appointed 2025-07-31
Joshua Brumm Appointed 2025-07-31
Jonathan McNeill Appointed 2025-07-31
Ellie Im Appointed 2025-07-31
Joshua Brumm Appointed 2025-07-31
Jonathan Violin Appointed 2025-06-18
Peter Harwin Appointed 2025-06-18
Susan Moran Appointed 2025-06-18
Joshua Brumm Appointed 2025-06-18
David Lubner Appointed 2025-06-18
Alexandra Balcom Appointed 2025-06-18
Barbara Bispham Appointed 2025-06-18
Ryan Lynch Appointed 2025-06-18
Peter Harwin Appointed 2025-06-18
Richard Scalzo Appointed 2025-06-18
Christopher Doughty Appointed 2025-06-18
Ellie Im Appointed 2025-06-18
Jonathan McNeill Appointed 2025-06-18
Joshua Brumm Appointed 2025-06-18
Brian Hahn Resigned 2025-06-18
Timothy Pearson
“On June 13, 2025, Patricia Andrews, Daniel Janius and Timothy Pearson resigned from the Company's board of directors and its committees on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company's operations, policies or practices.”
Resigned 2025-06-18

Leadership

Key facts CIK 1253689 CUSIP G2545C104 13F (30d) 102 filings 99 filers Visit website Investor relations